GLENMARK PHARMACEUTICALS
|
The Current P/B Ratio of GLENMARK PHARMACEUTICALS is 5.32.
Share Price | ₹1,477.0 | Jan 15,2025 |
Market Cap | ₹41,680.9 Cr | |
Book Value | ₹7,829.7 Cr | Mar2024 - Consolidated Results |
Price/Book | 5.32x | Calculated as MarketCap/Book Value |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PB (Price/Book ) ratio of GLENMARK PHARMACEUTICALS
P/B =
Market Capitalization
/ Book Value
or, using per-share numbers:
P/B = Stock Price /
Book Value Per Share
Current Market Cap [ ₹41,680.9 Cr] as on Jan 15,2025
(/) Book Value [ ₹7,829.7 Cr] based on Mar2024 - Consolidated Results
(=) P/B Ratio [ 5.32x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '5.32 times book value' to own 1 share of the company.
PB Multiples are one of the most widely used valuation multiple in industry.
Since P/B ratio uses Book Value in the calculation, P/B multiples are not always reliable for valuing companies with negative book value.
In such cases, you may consider using Price to Earnings ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
The chart below summarizes the trend in P/B Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PB (Price/Book ) ratio chart of GLENMARK PHARMACEUTICALS
PB Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/b ratio for fiscal years ending Mar2024 to Mar2020 averaged 1.81x.
- GLENMARK PHARMACEUTICALS 's operated at median p/b ratio of 1.39x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/b ratio peaked in Mar2024 at 3.45x.
- GLENMARK PHARMACEUTICALS 's p/b ratio hit its five-year low in Mar2020 of 0.96x.
How does GLENMARK PHARMACEUTICALS 's P/B Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Book Value | PB Ratio | Market Cap |
---|---|---|---|
GLENMARK PHARMACEUTICALS | 7,829.70 | 5.32 | 41,680.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 63,666.80 | 6.62 | 421,527.0 |
CIPLA LTD | 26,619.90 | 4.39 | 116,854.0 |
DR REDDYS LABORATORIES LTD | 28,123.50 | 3.97 | 111,746.0 |
ZYDUS LIFESCIENCES LTD | 19,829.50 | 5.00 | 99,093.9 |
DIVIS LABORATORIES LTD | 13,571.00 | 11.50 | 156,037.0 |
MANKIND PHARMA LTD | 9,339.84 | 11.46 | 107,078.0 |
TORRENT PHARMACEUTICALS LTD | 6,856.15 | 15.87 | 108,781.0 |
LUPIN LTD | 14,175.80 | 6.85 | 97,093.5 |
AUROBINDO PHARMA LTD | 29,842.80 | 2.23 | 66,638.3 |
ABBOTT INDIA LTD | 3,658.73 | 16.12 | 58,996.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PB Analysis vs GLENMARK PHARMACEUTICALS 's P/B Ratio
Top 10 Industry Peers | PB Ratio |
---|---|
Min industry PB | 2.23x |
Max industry PB | 16.12x |
Median industry PB | 6.62x |
Average industry PB | 8.12x |
You may also like the below Video Courses